

Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028

<https://marketpublishers.com/r/E21337190FE1EN.html>

Date: January 2023

Pages: 142

Price: US\$ 2,499.00 (Single User License)

ID: E21337190FE1EN

Abstracts

The global epilepsy drugs market size reached US\$ 2.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 3.52 Billion by 2028, exhibiting a growth rate (CAGR) of 8.2% during 2023-2028. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictable, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road

injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine
Topiramate
Pregabalin
Rufinamide
Zonisamide
Third Generation Drugs
Lacosamide
Perampanel
Eslicarbazepine Acetate
Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs
Broad-Spectrum AEDs

A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.

Distribution Channel Insights

Hospital Pharmacy
Pharmacy Stores
Others

A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in

the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global epilepsy drugs market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global epilepsy drugs market?

What are the key regional markets?

Which countries represent the most attractive epilepsy drugs markets?

What is the breakup of the market based on the generation type?

What is the breakup of the market based on the anti-epileptics drugs type?

What is the breakup of the market based on the distribution channel?

What is the competitive structure of the global epilepsy drugs market?

Who are the key players/companies in the global epilepsy drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL EPILEPSY DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY GENERATION TYPE

- 6.1 First Generation Drugs
 - 6.1.1 Market Trends
 - 6.1.2 Key Segments
 - 6.1.2.1 Phenytoin
 - 6.1.2.2 Carbamazepine
 - 6.1.2.3 Oxcarbazepine
 - 6.1.2.4 Valproate

- 6.1.2.5 Ethosuximide
- 6.1.2.6 Primidone
- 6.1.2.7 Phenobarbital
- 6.1.3 Market Forecast
- 6.2 Second Generation Drugs
 - 6.2.1 Market Trends
 - 6.2.2 Key Segments
 - 6.2.2.1 Levetiracetam
 - 6.2.2.2 Lamotrigine
 - 6.2.2.3 Topiramate
 - 6.2.2.4 Pregabalin
 - 6.2.2.5 Rufinamide
 - 6.2.2.6 Zonisamide
 - 6.2.3 Market Forecast
- 6.3 Third Generation Drugs
 - 6.3.1 Market Trends
 - 6.3.2 Key Segments
 - 6.3.2.1 Lacosamide
 - 6.3.2.2 Perampanel
 - 6.3.2.3 Eslicarbazepine Acetate
 - 6.3.2.4 Ezogabine/Retigabine
 - 6.3.3 Market Forecast

7 MARKET BREAKUP BY ANTI-EPILEPTICS DRUGS TYPE

- 7.1 Narrow-Spectrum AEDs
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Broad-Spectrum AEDs
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast

8 MARKET BREAKUP BY DISTRIBUTION CHANNEL

- 8.1 Hospital Pharmacy
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Pharmacy Stores
 - 8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Others

8.3.1 Market Trends

8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

9.1 North America

9.1.1 United States

9.1.1.1 Market Trends

9.1.1.2 Market Forecast

9.1.2 Canada

9.1.2.1 Market Trends

9.1.2.2 Market Forecast

9.2 Asia-Pacific

9.2.1 China

9.2.1.1 Market Trends

9.2.1.2 Market Forecast

9.2.2 Japan

9.2.2.1 Market Trends

9.2.2.2 Market Forecast

9.2.3 India

9.2.3.1 Market Trends

9.2.3.2 Market Forecast

9.2.4 South Korea

9.2.4.1 Market Trends

9.2.4.2 Market Forecast

9.2.5 Australia

9.2.5.1 Market Trends

9.2.5.2 Market Forecast

9.2.6 Indonesia

9.2.6.1 Market Trends

9.2.6.2 Market Forecast

9.2.7 Others

9.2.7.1 Market Trends

9.2.7.2 Market Forecast

9.3 Europe

9.3.1 Germany

9.3.1.1 Market Trends

- 9.3.1.2 Market Forecast
- 9.3.2 France
 - 9.3.2.1 Market Trends
 - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
- 9.3.4 Italy
 - 9.3.4.1 Market Trends
 - 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES

- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints

10.4 Opportunities

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Abbott Laboratories

14.3.1.1 Company Overview

14.3.1.2 Product Portfolio

14.3.1.3 Financials

14.3.1.4 SWOT Analysis

14.3.2 Alkem Laboratories Limited

14.3.2.1 Company Overview

14.3.2.2 Product Portfolio

14.3.2.3 Financials

14.3.2.4 SWOT Analysis

14.3.3 Bausch Health Companies Inc.

14.3.3.1 Company Overview

14.3.3.2 Product Portfolio

14.3.3.3 Financials

14.3.3.4 SWOT Analysis

14.3.4 Eisai Co. Ltd.

14.3.4.1 Company Overview

14.3.4.2 Product Portfolio

14.3.4.3 Financials

- 14.3.4.4 SWOT Analysis
- 14.3.5 GSK plc
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.5.3 Financials
 - 14.3.5.4 SWOT Analysis
- 14.3.6 H. Lundbeck A/S
 - 14.3.6.1 Company Overview
 - 14.3.6.2 Product Portfolio
 - 14.3.6.3 Financials
 - 14.3.6.4 SWOT Analysis
- 14.3.7 Jazz Pharmaceuticals plc
 - 14.3.7.1 Company Overview
 - 14.3.7.2 Product Portfolio
 - 14.3.7.3 Financials
 - 14.3.7.4 SWOT Analysis
- 14.3.8 Novartis AG
 - 14.3.8.1 Company Overview
 - 14.3.8.2 Product Portfolio
 - 14.3.8.3 Financials
 - 14.3.8.4 SWOT Analysis
- 14.3.9 Pfizer Inc.
 - 14.3.9.1 Company Overview
 - 14.3.9.2 Product Portfolio
 - 14.3.9.3 Financials
 - 14.3.9.4 SWOT Analysis
- 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
 - 14.3.10.1 Company Overview
 - 14.3.10.2 Product Portfolio
 - 14.3.10.3 SWOT Analysis
- 14.3.11 UCB S.A.
 - 14.3.11.1 Company Overview
 - 14.3.11.2 Product Portfolio
 - 14.3.11.3 Financials
 - 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List Of Tables

LIST OF TABLES

Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2022 & 2028

Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million US\$), 2023-2028

Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million US\$), 2023-2028

Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million US\$), 2023-2028

Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million US\$), 2023-2028

Table 6: Global: Epilepsy Drugs Market: Competitive Structure

Table 7: Global: Epilepsy Drugs Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges

Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion US\$), 2017-2022

Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion US\$), 2023-2028

Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2022

Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2022

Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2022

Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2022

Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),

2023-2028

Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017
& 2022

Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million
US\$), 2023-2028

Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 &
2022

Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$),
2023-2028

Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2022

Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities

Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis

Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

I would like to order

Product name: Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028

Product link: <https://marketpublishers.com/r/E21337190FE1EN.html>

Price: US\$ 2,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E21337190FE1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970